Protective effects of a bacterially expressed NIF-KGF fusion protein against bleomycin-induced acute lung injury in mice.
Current evidence suggests that the keratinocyte growth factor (KGF) and the polymorphonuclear leukocyte may play key roles in the development of lung fibrosis. Here we describe the construction, expression, purification, and identification of a novel NIF (neutrophil inhibitory factor)-KGF mutant fusion protein (NKM). The fusion gene was ligated via a flexible octapeptide hinge and expressed as an insoluble protein in Escherichia coli BL21 (DE3). The fusion protein retained the activities of KGF and NIF, as it inhibited both fibroblast proliferation and leukocyte adhesion. Next, the effects of NKM on bleomycin-induced lung fibrosis in mice were examined. The mice were divided into the following four groups: (i) saline group; (ii) bleomycin group (instilled with 5 mg/kg bleomycin intratracheally); (iii) bleomycin plus dexamethasone (Dex) group (Dex was given intraperitoneally (i.p.) at 1 mg/kg/day 2 days prior to bleomycin instillation and daily after bleomycin instillation until the end of the treatment); and (iv) bleomycin plus NKM group (NKM was given i.p. at 2 mg/kg/day using the same protocol as the Dex group). NKM significantly improved the survival rates of mice exposed to bleomycin. The marked morphological changes and increased hydroxyproline levels resulted from the instillation of bleomycin (on Day 17) in the lungs were significantly inhibited by NKM. These results revealed that NKM can attenuate bleomycin-induced lung fibrosis, suggesting that NKM could be used to prevent bleomycin-induced lung damage or other interstitial pulmonary fibrosis.
Li
Xinping
X
Department of Animal Biotechnology, Northwest Sci-tech University of Agriculture and Forestry, Yangling, China. lxp67cqu@163.com
Li
Shengli
S
Zhang
Miaotao
M
Li
Xiukun
X
Zhang
Xiaoming
X
Zhang
Wenlong
W
Li
Chuanghong
C
D055371:Acute Lung Injury / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D001761:Bleomycin; D015153:Blotting, Western; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D003001:Cloning, Molecular; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000235:genetics; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D015870:Gene Expression; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D015801:Helminth Proteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D006909:Hydroxyproline / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D008969:Molecular Sequence Data; D041681:NIH 3T3 Cells; D009504:Neutrophils / Q000378:metabolism; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*
D006023:Glycoproteins; D015801:Helminth Proteins; D008565:Membrane Proteins; D011993:Recombinant Fusion Proteins; D001761:Bleomycin; D051523:Fibroblast Growth Factor 7; C086581:NIF protein, Ancylostoma caninum; D006909:Hydroxyproline